147 related articles for article (PubMed ID: 37831066)
21. Prognostic factors affecting survival in metastatic soft tissue sarcoma: an analysis of 110 patients.
Iqbal N; Shukla NK; Deo SV; Agarwala S; Sharma DN; Sharma MC; Bakhshi S
Clin Transl Oncol; 2016 Mar; 18(3):310-6. PubMed ID: 26243399
[TBL] [Abstract][Full Text] [Related]
22. Prognostic factors and outcomes of adult spermatic cord sarcoma. A study from the French Sarcoma Group.
Achard G; Charon-Barra C; Carrere S; Bonvalot S; Meeus P; Fau M; Honoré C; Delhorme JB; Tzanis D; Le Loarer F; Karanian-Philippe M; Ngo C; Le Guellec S; Bertaut A; Causeret S; Isambert N
Eur J Surg Oncol; 2023 Jul; 49(7):1203-1208. PubMed ID: 36868941
[TBL] [Abstract][Full Text] [Related]
23. Prognostic factors in adolescents and young adults (AYA) with high risk soft tissue sarcoma (STS) treated by adjuvant chemotherapy: a study based on pooled European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62771 and 62931.
Kasper B; Ouali M; van Glabbeke M; Blay JY; Bramwell VH; Woll PJ; Hohenberger P; Schöffski P
Eur J Cancer; 2013 Jan; 49(2):449-56. PubMed ID: 22975215
[TBL] [Abstract][Full Text] [Related]
24. Indistinguishable genomic profiles and shared prognostic markers in undifferentiated pleomorphic sarcoma and leiomyosarcoma: different sides of a single coin?
Carneiro A; Francis P; Bendahl PO; Fernebro J; Akerman M; Fletcher C; Rydholm A; Borg A; Nilbert M
Lab Invest; 2009 Jun; 89(6):668-75. PubMed ID: 19290004
[TBL] [Abstract][Full Text] [Related]
25. Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study.
Bilici A; Koca S; Karaagac M; Aydin SG; Eraslan E; Kaplan MA; Ocak B; Goksu SS; Paydas S; Akgul F; Derin S; Ergun Y; Yekeduz E; Erol C; Ozyukseler DT; Demiray AG; Karaca M; Guc ZG; Menekse S; Cinkir HY; Gumusay O; Sakin A; Ozkul O; Demir H; Erdem D; Besiroglu M; Unal OU; Acar R; Koral L; Sahin S; Sakalar T; Bahceci A; Ozveren A; Gunaydin UM; Seker MM; Sunar V; Dal P; Artac M; Turhal S
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8243-8253. PubMed ID: 37067546
[TBL] [Abstract][Full Text] [Related]
26. The Prognostic Value of Lymphovascular Invasion in Truncal and Extremity Soft Tissue Sarcomas: An Analysis from the National Cancer Database.
Ethun CG; Lopez-Aguiar AG; Switchenko JM; Gillespie TW; Delman KA; Staley CA; Maithel SK; Cardona K
Ann Surg Oncol; 2019 Dec; 26(13):4723-4729. PubMed ID: 31502023
[TBL] [Abstract][Full Text] [Related]
27. Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.
Patel S; von Mehren M; Reed DR; Kaiser P; Charlson J; Ryan CW; Rushing D; Livingston M; Singh A; Seth R; Forscher C; D'Amato G; Chawla SP; McCarthy S; Wang G; Parekh T; Knoblauch R; Hensley ML; Maki RG; Demetri GD
Cancer; 2019 Aug; 125(15):2610-2620. PubMed ID: 31173362
[TBL] [Abstract][Full Text] [Related]
28. Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group.
Gronchi A; Stacchiotti S; Verderio P; Ferrari S; Martin Broto J; Lopez-Pousa A; Llombart-Bosch A; Dei Tos AP; Collini P; Jurado JC; De Paoli A; Donati DM; Poveda A; Quagliuolo V; Comandone A; Grignani G; Morosi C; Messina A; De Sanctis R; Bottelli S; Palassini E; Casali PG; Picci P
Ann Oncol; 2016 Dec; 27(12):2283-2288. PubMed ID: 27733375
[TBL] [Abstract][Full Text] [Related]
29. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients.
Karavasilis V; Seddon BM; Ashley S; Al-Muderis O; Fisher C; Judson I
Cancer; 2008 Apr; 112(7):1585-91. PubMed ID: 18278813
[TBL] [Abstract][Full Text] [Related]
30. Minimal Increase in Survival Throughout the Years in Patients with Soft Tissue Sarcoma with Synchronous Metastases: Results of a Population-Based Study.
Vos M; Ho VKY; Oosten AW; Verhoef C; Sleijfer S
Oncologist; 2019 Jul; 24(7):e526-e535. PubMed ID: 30190301
[TBL] [Abstract][Full Text] [Related]
31. Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
D'Ambrosio L; Touati N; Blay JY; Grignani G; Flippot R; Czarnecka AM; Piperno-Neumann S; Martin-Broto J; Sanfilippo R; Katz D; Duffaud F; Vincenzi B; Stark DP; Mazzeo F; Tuchscherer A; Chevreau C; Sherriff J; Estival A; Litière S; Sents W; Ray-Coquard I; Tolomeo F; Le Cesne A; Rutkowski P; Stacchiotti S; Kasper B; Gelderblom H; Gronchi A;
Cancer; 2020 Jun; 126(11):2637-2647. PubMed ID: 32129883
[TBL] [Abstract][Full Text] [Related]
32. Notch pathway inhibition with LY3039478 in soft tissue sarcoma and gastrointestinal stromal tumours.
Mir O; Azaro A; Merchan J; Chugh R; Trent J; Rodon J; Ohnmacht U; Diener JT; Smith C; Yuen E; Oakley GJ; Le Cesne A; Soria JC; Benhadji KA; Massard C
Eur J Cancer; 2018 Nov; 103():88-97. PubMed ID: 30218977
[TBL] [Abstract][Full Text] [Related]
33. Real-World Experiences with Pazopanib in Patients with Advanced Soft Tissue and Bone Sarcoma in Northern California.
Seto T; Song MN; Trieu M; Yu J; Sidhu M; Liu CM; Sam D; Pan M
Med Sci (Basel); 2019 Mar; 7(3):. PubMed ID: 30889920
[No Abstract] [Full Text] [Related]
34. The clinical outcome of eribulin treatment in Japanese patients with advanced soft tissue sarcoma: a Tokai Musculoskeletal Oncology Consortium study.
Nakamura T; Tsukushi S; Asanuma K; Katagiri H; Ikuta K; Nagano A; Kozawa E; Yamada S; Shido Y; Yamada K; Kawanami K; Ishimura D; Sudo A; Nishida Y
Clin Exp Metastasis; 2019 Aug; 36(4):343-350. PubMed ID: 31209624
[TBL] [Abstract][Full Text] [Related]
35. Survival impact of centralization and clinical guidelines for soft tissue sarcoma (A prospective and exhaustive population-based cohort).
Derbel O; Heudel PE; Cropet C; Meeus P; Vaz G; Biron P; Cassier P; Decouvelaere AV; Ranchere-Vince D; Collard O; De Laroche E; Thiesse P; Farsi F; Cellier D; Gilly FN; Blay JY; Ray-Coquard I
PLoS One; 2017; 12(2):e0158406. PubMed ID: 28158190
[TBL] [Abstract][Full Text] [Related]
36. Sex- and Co-Mutation-Dependent Prognosis in Patients with SMARCA4-Mutated Malignancies.
Pan M; Jiang C; Zhang Z; Achacoso N; Solorzano-Pinto AV; Tse P; Chung E; Suga JM; Thomas S; Habel LA
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345003
[TBL] [Abstract][Full Text] [Related]
37. Prognostic relevance of distant metastases versus locally advanced disease in soft tissue sarcomas: An EORTC-STBSG database study.
Verschoor AJ; Litière S; Marréaud S; Judson I; Toulmonde M; Wardelmann E; van der Graaf WT; Le Cesne A; Gronchi A; Gelderblom H
Eur J Cancer; 2018 May; 94():187-198. PubMed ID: 29574364
[TBL] [Abstract][Full Text] [Related]
38. Factors affecting prognosis and treatment strategies in metastatic soft tissue sarcomas: twenty years of experience.
İlhan A; Eraslan E; Yildiz F; Arslan ÜY; Alkiş N
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(21):6465-6472. PubMed ID: 34787850
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma.
Dickson MA; Mahoney MR; Tap WD; D'Angelo SP; Keohan ML; Van Tine BA; Agulnik M; Horvath LE; Nair JS; Schwartz GK
Ann Oncol; 2016 Oct; 27(10):1855-60. PubMed ID: 27502708
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential.
Francis P; Namløs HM; Müller C; Edén P; Fernebro J; Berner JM; Bjerkehagen B; Akerman M; Bendahl PO; Isinger A; Rydholm A; Myklebost O; Nilbert M
BMC Genomics; 2007 Mar; 8():73. PubMed ID: 17359542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
